Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1478309 | 1.00 | PRCP (0.37) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL16223532 | 0.93 | CYP3A4 (0.42) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL541070 | 0.85 | CYP3A4 (0.39) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL1478863 | 0.85 | CYP3A4 (0.39) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL883160 | 0.83 | CYP3A4 (0.48) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL16223516 | 0.82 | CYP3A4 (0.46) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL12328183 | 0.77 | CYP3A4 (0.53) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL751258 | 0.76 | PRCP (0.42) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL1478326 | 0.75 | PRCP (0.36) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL1478311 | 0.75 | PRCP (0.36) | PRCPCYP3A4CYP2C9KCNH2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110077280-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077280-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | PRCP 573/4885CYP3A4 3387/4885CYP2C9 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.